title: Survival of patients with Ewing's sarcoma in Yazd-Iran.
abstract: BACKGROUND
  The Ewing's sarcoma family is a group of small round cell tumors which accounts for 10-15% of all primary bone neoplasms. The aim of this study was to evaluate the survival of Ewing's sarcoma patients in our province and to determine of influencing factors.
  
  
  METHODS
  All patients with documented Ewing's sarcoma/ primitive neuroectodermal tumor(PNET) family pathology were enrolled in this study during a period of eight years. For all of them local and systemic therapy were carried out. Overall and event free survival and prognostic factors were evaluated.
  
  
  RESULTS
  Thirty two patients were enrolled in the study. The median age was 17.5 years. Twenty (65.2%) were male and 9 (28.1%) were aged 14 years or less. Mean disease free survival was 26.8 (95%CI; 13.8-39.9) months and five year disease free survival was 26%. Mean overall survival was 38.7 months (95%CI; 25.9-50.6) and median overall survival was 24 months. Five year overall survival was 25%. From the variables evaluated , only presence of metastatic disease at presentation (p value=0. 028) and complete response (p value =0. 006) had significant relations to overall survival.
  
  
  CONCLUSIONS
  Survival of Ewing's sarcoma in our province is disappointing. It seems to be mostly due to less effective treatment. Administration of adequate chemotherapy dosage, resection of tumor with negative margins and precise assessment of irradiation volume may prove helpful.
authors.affiliation: Department of Radiotherapy, Isfahan University of Medical Sciences, Isfahan, Iran E-mail : Binesh44@yahoo.com.
authors.forename: Ali
authors.initials: A
authors.lastname: Akhavan
authors.forename: Fariba
authors.initials: F
authors.lastname: Binesh
authors.forename: Hadi
authors.initials: H
authors.lastname: Shamshiri
authors.forename: Fazllolah
authors.initials: F
authors.lastname: Ghanadi
mesh_terms: D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007492:Iran; D008297:Male; D009367:Neoplasm Staging; D018242:Neuroectodermal Tumors, Primitive / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012512:Sarcoma, Ewing / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D055815:Young Adult